American Society of Clinical Oncology. (2023) Pancreatic Cancer Statistics. Cancer.Net . https://www.cancer.net/cancer-types/pancreatic-cancer/statistics#:~:text=It%20is%20the%20fourth%20leading,worldwide%20died%20from%20pancreatic%20cancer .
Yermilov I, Bentrem D, Sekeris E et al (2009) Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal. Ann Surg Oncol 16(3):554–561. https://doi.org/10.1245/s10434-008-0178-6
Mantzavinou A, Uppara M, Chan J, Patel B (2022) Robotic versus open pancreaticoduodenectomy, comparing therapeutic indexes; a systematic review. Int J Surg 101:106633. https://doi.org/10.1016/j.ijsu.2022.106633
van Oosten AF, Ding D, Habib JR et al (2021) Perioperative outcomes of robotic pancreaticoduodenectomy: a propensity-matched analysis to open and laparoscopic pancreaticoduodenectomy. J Gastrointest Surg 25(7):1795–1804. https://doi.org/10.1007/s11605-020-04869-z
Shyr YM, Wang SE, Chen SC, Shyr BU (2020) Robotic pancreaticoduodenectomy in the era of minimally invasive surgery. J Chin Med Assoc 83(7):639–643. https://doi.org/10.1097/JCMA.0000000000000333
Ross S, Sucandy I, Vasanthakumar P, Christodoulou M, Pattilachan T, Rosemurgy A (2024) A comparative analysis of robotic versus open pancreaticoduodenectomy in octogenarians. J Robot Surg 18(1):183. https://doi.org/10.1007/s11701-024-01952-4
Rosemurgy AS, Ross SB, Espeut A et al (2022) Survival and robotic approach for pancreaticoduodenectomy: a propensity score-match study. J Am Coll Surg 234(4):677–684. https://doi.org/10.1097/XCS.0000000000000137
Zimmerman AM, Roye DG, Charpentier KP (2018) A comparison of outcomes between open, laparoscopic and robotic pancreaticoduodenectomy. HPB 20(4):364–369. https://doi.org/10.1016/j.hpb.2017.10.008
Ross S, Sucandy I, Vasanthakumar P, Espeut A, Christodoulou M, Pattilachan TM, Rosemurgy A (2024) Deconstructing the operative times of robotic pancreaticoduodenectomy. Am Surg 90(6):1521–1530. https://doi.org/10.1177/00031348241241705
Rosemurgy A, Ross S, Bourdeau T et al (2021) Cost analysis of pancreaticoduodenectomy at a high-volume robotic hepatopancreaticobiliary surgery program. J Am Coll Surg 232(4):461–469. https://doi.org/10.1016/j.jamcollsurg.2020.12.062
Jin J, Shi Y, Chen M et al (2021) Robotic versus open pancreatoduodenectomy for pancreatic and periampullary tumors (portal): a study protocol for a multicenter phase III non-inferiority randomized controlled trial. Trials 22:954. https://doi.org/10.1186/s13063-021-05939-6
Article PubMed PubMed Central Google Scholar
Ramanathan R, Mason T, Wolfe LG, Kaplan BJ (2018) Predictors of short-term readmission after pancreaticoduodenectomy. J Gastrointest Surg 22(6):998–1006. https://doi.org/10.1007/s11605-018-3700-6
Brown CS, Montgomery JR, Neiman PU et al (2021) Assessment of potentially preventable hospital readmissions after major surgery and association with public vs private health insurance and comorbidities. JAMA Netw Open 4(4):e215503. https://doi.org/10.1001/jamanetworkopen.2021.5503
Article PubMed PubMed Central Google Scholar
Fong ZV, Ferrone CR, Thayer SP et al (2014) Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them? J Gastrointest Surg 18(1):137–145. https://doi.org/10.1007/s11605-013-2336-9
Acher AW, Barrett JR, Schwartz PB et al (2021) Early vs late readmissions in pancreaticoduodenectomy patients: recognizing comprehensive episodic cost to help guide bundled payment plans and hospital resource allocation. J Gastrointest Surg 25(1):178–185. https://doi.org/10.1007/s11605-020-04714-3
Chhabra KR, Ibrahim AM, Thumma JR, Ryan AM, Dimick JB (2019) Impact of medicare readmissions penalties on targeted surgical conditions. Health Aff 38(7):1207–1215. https://doi.org/10.1377/hlthaff.2019.00096
Figueroa JF, Wadhera RK (2022) A decade of observing the hospital readmission reductions program—time to retire an ineffective policy. JAMA Netw Open 5(11):e2242593. https://doi.org/10.1001/jamanetworkopen.2022.42593
Palen A, Garnier J, Ewald J, Delpero JR, Turrini O (2023) Readmission after pancreaticoduodenectomy: birmingham score validation. HPB 25(2):172–178. https://doi.org/10.1016/j.hpb.2022.08.002
Mosquera C, Vohra NA, Fitzgerald TL, Zervos EE (2016) Discharge with pancreatic fistula after pancreaticoduodenectomy independently predicts hospital readmission. Am Surg 82(8):698–703
Rosemurgy AS, Luberice K, Paul H et al (2012) Readmissions after pancreaticoduodenectomy: efforts need to focus on patient expectations and nonhospital medical care. Am Surg 78(8):837–843
van Geenen RCI, van Gulik TM, Busch ORC, de Wit LT, Obertop H, Gouma DJ (2002) Readmissions after pancreatoduodenectomy. Br J Surg 88(11):1467–1471. https://doi.org/10.1046/j.0007-1323.2001.01900.x
Sutton JM, Wilson GC, Wima K et al (2015) Readmission after pancreaticoduodenectomy: the influence of the volume effect beyond mortality. Ann Surg Oncol 22(12):3785–3792. https://doi.org/10.1245/s10434-015-4451-1
Noba L, Rodgers S, Doi L, Chandler C, Hariharan D, Yip V (2023) Costs and clinical benefits of enhanced recovery after surgery (ERAS) in pancreaticoduodenectomy: an updated systematic review and meta-analysis. J Cancer Res Clin Oncol 149(9):6639–6660. https://doi.org/10.1007/s00432-022-04508-x
Article PubMed PubMed Central Google Scholar
Cienfuegos JA, Hurtado-Pardo L, Breeze CE et al (2023) Predictors of postoperative complications and readmissions in laparoscopic pancreas resection: Results of a cohort 105 consecutive cases. A retrospective study Cir Esp 101(5):333–340. https://doi.org/10.1016/j.cireng.2022.04.015
Pappalardo A, Giunta EF, Tirino G, Pompella L, Federico P, Daniele B, De Vita F, Petrillo A (2021) Adjuvant treatment in pancreatic cancer: shaping the future of the curative setting. Front Oncol 11:695627. https://doi.org/10.3389/fonc.2021.695627
Article CAS PubMed PubMed Central Google Scholar
Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P, Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group (2022) Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol 8(11):1571–1578. https://doi.org/10.1001/jamaoncol.2022.3829
Article PubMed PubMed Central Google Scholar
Koerner AS, Thomas AS, Chabot JA, Kluger MD, Sugahara KN, Schrope BA (2023) Associations between patient characteristics and whipple procedure outcomes before and after implementation of an enhanced recovery after surgery protocol. J Gastrointest Surg 27(9):1855–1866. https://doi.org/10.1007/s11605-023-05693-x
Feferman Y, Katz M, Egorova N, Sarpel U, Bickell N (2022) Preventable readmissions following common cancer surgeries: lessons learned from New York state and targets for improvement. Isr Med Assoc J 24(1):33–41
Curfman KR, Poola AS, Blair GE et al (2023) Ambulatory colectomy: a pathway for advancing the enhanced recovery protocol. J Robot Surg 17:827–834. https://doi.org/10.1007/s11701-022-01463-0
Minervini F, Taylor J, Hanna WC et al (2022) Can a mobile app technology reduce emergency department visits and readmissions after lung resection? A prospective cohort study. Can J Surg 65(6):E798–E804. https://doi.org/10.1503/cjs.000122
留言 (0)